Pooling over 260 mCRPC patients from six different centers, however, contrary findings on long-term PSA-based progression-free survival were described, indicating that higher PSMA-avid tumor burden was associated with more favorable OS [16]. The gene discussed is FOLH1; the disease is neoplasm.